Hims & Hers Health Target of Unusually Large Options Trading (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) was the recipient of some unusual options trading on Monday. Stock investors acquired 38,942 call options on the company. This is an increase of approximately 19% compared to the typical daily volume of 32,705 call options.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several research reports. Bank of America dropped their price target on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, September 13th. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Truist Financial boosted their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Finally, Piper Sandler reissued a “neutral” rating and issued a $18.00 price target on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Moderate Buy” and a consensus price target of $19.86.

Hims & Hers Health Stock Performance

HIMS stock opened at $18.75 on Wednesday. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $25.74. The stock’s 50 day moving average price is $16.50 and its 200 day moving average price is $17.31. The firm has a market cap of $4.03 billion, a P/E ratio of -1,877.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. During the same quarter in the previous year, the business earned ($0.03) EPS. Hims & Hers Health’s quarterly revenue was up 51.8% compared to the same quarter last year. On average, research analysts predict that Hims & Hers Health will post 0.22 earnings per share for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 9,313 shares of the stock in a transaction on Friday, July 12th. The stock was sold at an average price of $22.00, for a total value of $204,886.00. Following the sale, the insider now owns 185,326 shares in the company, valued at $4,077,172. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Hims & Hers Health news, insider Michael Chi sold 9,313 shares of the company’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $22.00, for a total value of $204,886.00. Following the transaction, the insider now owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $16.47, for a total transaction of $3,110,985.36. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $551,777.94. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 573,618 shares of company stock valued at $9,329,808. 17.71% of the stock is currently owned by corporate insiders.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its stake in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares in the last quarter. Quest Partners LLC increased its holdings in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares in the last quarter. Van ECK Associates Corp purchased a new stake in shares of Hims & Hers Health in the second quarter worth approximately $111,000. CWM LLC lifted its holdings in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares in the last quarter. Finally, Amalgamated Bank boosted its position in shares of Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.